{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:01:41Z","timestamp":1793142101866,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using a sample representative of the US adult population with regard to sex, age, and ethnicity (\n                      <jats:italic>N<\/jats:italic>\n                      =2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among respondents who reported lifetime psychedelic use (\n                      <jats:italic>n<\/jats:italic>\n                      =613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-023-06478-5","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T02:02:10Z","timestamp":1698112930000},"page":"1577-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Psychedelic use and psychiatric risks"],"prefix":"10.1007","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-7566","authenticated-orcid":false,"given":"Otto","family":"Simonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6888-0126","authenticated-orcid":false,"given":"Simon B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-7319","authenticated-orcid":false,"given":"Walter","family":"Osika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"6478_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental diseases (DSM-V), 5th edn","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental diseases (DSM-V), 5th edn. American Psychiatric Association Press, Washington, DC"},{"issue":"2","key":"6478_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KA Andersen","year":"2021","unstructured":"Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021) Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand 143(2):101\u2013118","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"6478_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugalcdep.2010.09.006","volume":"114","author":"MJ Baggott","year":"2011","unstructured":"Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 114(1):61\u201367","journal-title":"Drug Alcohol Depend"},{"issue":"15","key":"6478_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411","journal-title":"N Engl J Med"},{"issue":"4","key":"6478_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G* Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41(4):1149\u20131160","journal-title":"Behav Res Methods"},{"issue":"2","key":"6478_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","volume":"238","author":"NL Galv\u00e3o-Coelho","year":"2021","unstructured":"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 238(2):341\u2013354","journal-title":"Psychopharmacology"},{"key":"6478_CR7","first-page":"100240","volume":"6","author":"DE Gard","year":"2021","unstructured":"Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS et al (2021) Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep 6:100240","journal-title":"J Affect Disord Rep"},{"issue":"18","key":"6478_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648","journal-title":"N Engl J Med"},{"key":"6478_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_457","volume-title":"Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences","author":"JH Halpern","year":"2016","unstructured":"Halpern JH, Lerner AG, Passie T (2016) A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. In: Halberstadt AL, Vollenweider FX, Nichols DE (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin. https:\/\/doi.org\/10.1007\/7854_2016_457"},{"issue":"2","key":"6478_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","volume":"69","author":"JH Halpern","year":"2003","unstructured":"Halpern JH, Pope HG Jr (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 69(2):109\u2013119","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"6478_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"issue":"8","key":"6478_CR12","doi-asserted-by":"publisher","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen P\u00d8 (2013) Psychedelics and mental health: a population study. PLoS One 8(8):e63972","journal-title":"PLoS One"},{"issue":"6","key":"6478_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1600-0447.2010.01633.x","volume":"123","author":"N Kuzenko","year":"2011","unstructured":"Kuzenko N, Sareen J, Beesdo-Baum K, Perkonigg A, H\u00f6fler M, Simm J et al (2011) Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample. Acta Psychiatr Scand 123(6):466\u2013474","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"6478_CR14","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.1038\/s41598-021-94421-z","volume":"11","author":"AV Lebedev","year":"2021","unstructured":"Lebedev AV, Acar K, Garz\u00f3n B, Almeida R, R\u00e5back J, \u00c5berg A et al (2021) Psychedelic drug use and schizotypy in young adults. Sci Rep 11(1):15058","journal-title":"Sci Rep"},{"issue":"6","key":"6478_CR15","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","volume":"239","author":"F M\u00fcller","year":"2022","unstructured":"M\u00fcller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y et al (2022) Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology 239(6):1933\u20131943","journal-title":"Psychopharmacology"},{"key":"6478_CR16","doi-asserted-by":"publisher","first-page":"205032452210852","DOI":"10.1177\/20503245221085222","volume":"8","author":"J Roscoe","year":"2022","unstructured":"Roscoe J, Lozy O (2022) Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci Policy Law 8:20503245221085222","journal-title":"Drug Sci Policy Law"},{"issue":"7","key":"6478_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","volume":"173","author":"DM Ruderfer","year":"2018","unstructured":"Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW et al (2018) Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173(7):1705\u20131715","journal-title":"Cell"},{"issue":"3","key":"6478_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022) Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol 36(3):258\u2013272","journal-title":"J Psychopharmacol"},{"issue":"4","key":"6478_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269881121996863","volume":"35","author":"O Simonsson","year":"2021","unstructured":"Simonsson O, Sexton JD, Hendricks PS (2021) Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol 35(4):447\u2013452","journal-title":"J Psychopharmacol"},{"issue":"10","key":"6478_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ (1984) Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172(10):577\u2013595","journal-title":"J Nerv Ment Dis"},{"key":"6478_CR21","doi-asserted-by":"crossref","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56(101809)","DOI":"10.1016\/j.eclinm.2022.101809"},{"issue":"8","key":"6478_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/archpsyc.58.8.787","volume":"58","author":"M Zimmerman","year":"2001","unstructured":"Zimmerman M, Mattia JI (2001) A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 58(8):787\u2013794","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06478-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:41:55Z","timestamp":1751517715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6478"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06478-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was deemed to be exempt by the Internal Review Board (IRB) at UW-Madison.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"PSH has been in paid advisory relationships with the following organizations regarding the development of psychedelics and related compounds: Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, Journey Colab Corporation, Reset Pharmaceuticals Inc., and Silo Pharma. OS and RC were co-founders of Eudelics AB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}